|Day Low/High||39.09 / 39.51|
|52 Wk Low/High||31.99 / 40.16|
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI ® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on...
AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date.
AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed...
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or...
Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
AstraZeneca and Merck & Co., Inc.
AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA ® (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June...
AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company's Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American...
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.
Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.
Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!
U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.
I continue to see these names as bargains in the biotech and biopharma space.
SHANGHAI, June 6, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd.
Nektar Therapeutics shares got destroyed on Monday. Here is why.
AstraZeneca and Merck & Co., Inc.
AstraZeneca and MedImmune, its global biologics research and development arm, today presented results from the Phase III ('1053') clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.